Saturday, Sep 19 2020 | Time 05:26 Hrs(IST)
image
  • Europe braces itself for a second wave of the COVID pandemic as winter approaches
  • Level 3 COVID-19 response declared for Irish capital Dublin
  • War against COVID-19: New rules of engagement in MP
  • MP CM’s condolences
  • More than 22k pattas to be given out in MP
  • War against COVID-19: MP gets another ICU
  • US to ban app downloads of TikTok and WeChat within 48 hours
  • Boris Johnson says second wave of COVID-19 hitting the UK
  • US to keep reviewing commercial proposals for TikTok, despite looming ban - Pompeo
  • European Commission signs second COVID-19 vaccine contract
  • Canada shelves free trade negotiations with China
  • Flood stares at Nanded, Godavari filled up to brim
  • Turkish President Erdogan to visit Bangladesh early 2021 to join D-8 summit
  • Madrid region introduces new COVID-19 restrictions
  • Centre repatriates NATGRID Director Shiv Narayan to his cadre
Business Economy


Covistat, Biopharmaceutical Company Developing Low-Cost COVID-19 Treatment, Acquires IP From World Leader in Respiratory Disease Medicine

SAN DIEGO, Aug. 6, 2020 /PRNewswire/ -- A biopharmaceutical company repurposing nafamostat, a generic remedy for pancreatitis and acute kidney injury, is one step closer to a treatment in its fight against COVID-19. Covistat, an Ensysce Biosciences subsidiary, today announced its acquisition of Mucokinetica's technology and intellectual property, which will accelerate efforts to develop a low-cost treatment that helps the body's ability to block the coronavirus—and its mutating variations—from infiltrating our cells.
London-based Dr. Peter Cole and Dr. Rod Hall, founders of Mucokinetica Ltd. and world-leading experts in the development of medicines to treat respiratory diseases such as cystic fibrosis, are joining the Covistat team.
Nafamostat, with its anticoagulant and anti-inflammatory properties, has for 30 years been safely used intravenously to treat pancreatitis patients. Nafamostat works by affecting the body's own enzymes—not the virus, which is capable of mutating to evade treatments. Nafamostat blocks TMPRSS2, the enzyme that enables SARS-CoV-2's spike proteins to gain entry into cells. Whether suffering from mild symptoms at home or acute respiratory failure in a hospital, nafamostat's therapy is expected to reduce the viral load in patients and prevent the progression of COVID-19.
More News

ViewSonic Launches New, All-in-One Direct View LED Displays with Sizes of Up to 216"

18 Sep 2020 | 10:34 PM

BREA, California, Sept. 18, 2020 /PRNewswire/ -- ViewSonic Corp., a leading global provider of visual solutions, is introducing its latest All-in-One Direct View LED Displays, a brand-new addition to the large-size presentation display sector. Different from traditional LED displays, these new displays integrate display, image stitching, power supply, and control systems into one device that offers easy installation, operation, and maintenance. The elegant design of the All-in-One Direct View LED Display elevates the seamless viewing experience and easily merges with the surrounding environment in spaces such as lobbies, auditoriums, boardrooms, and conference rooms.

see more..

Govt allows higher local content requirement for public procurement

18 Sep 2020 | 10:00 PM

New Delhi, Sep 18 (UNI) The Centre has expanded the scope for local content requirement in public procurement tenders by allowing departments and ministries to mandate higher than minimum 50 per cent and 20 per cent local content stipulated earlier for two separate categories of local suppliers.

see more..

Innovation fuels growth for retail and telecom sectors in BrandZ™

18 Sep 2020 | 9:01 PM

Mumbai, Sept 18 (UNI) Retail and telecom brands have outperformed most other categories and seen their brand value increase in the 2020 BrandZ™ Top 75 Most Valuable Indian Brands ranking, released today by WPP and Kantar.

see more..

UP ropes in banks to credit Rs 15,000 cr finance to MSME units

18 Sep 2020 | 8:45 PM

Lucknow, Sep 18 (UNI) Utilising the facility extended by the Rs 20 lakh crore 'Aatmanirbhar Bharat Abhiyan' package announced by Union Finance Minister Nirmala Sitharaman in May, Uttar Pradesh government has roped in the banks to extend the credit of Rs 15,000 crore to the micro, small and medium enterprises (MSMEs) in the short term to overcome the working capital woes during the Covid-19 pandemic.

see more..

Angel Broking Limited Initial Public Offer to open on 22nd September 2020

18 Sep 2020 | 8:11 PM

Kolkata, Sep 18 (UNI) Angel Broking Limited, one of the largest retail broking houses in India in terms of active clients on NSE as of June 30, 2020, will open the initial public offer of equity shares of face value of Rs 10 each (“Equity Shares” and such initial public offer, the “Offer”) on 22nd September 2020.

see more..
image